Rankings
▼
Calendar
ICCC Q1 2023 Earnings — ImmuCell Corporation Revenue & Financial Results | Market Cap Arena
ICCC
ImmuCell Corporation
$60M
Q1 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$3M
-42.6% YoY
Gross Profit
$300,775
8.7% margin
Operating Income
-$2M
-65.5% margin
Net Income
-$2M
-67.2% margin
EPS (Diluted)
$-0.30
QoQ Revenue Growth
-11.9%
Cash Flow
Operating Cash Flow
-$3M
Free Cash Flow
-$3M
Stock-Based Comp.
$96,116
Balance Sheet
Total Assets
$43M
Total Liabilities
$15M
Stockholders' Equity
$28M
Cash & Equivalents
$3M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$3M
$6M
-42.6%
Gross Profit
$300,775
$3M
-90.3%
Operating Income
-$2M
$570,609
-495.4%
Net Income
-$2M
$513,287
-551.0%
← FY 2023
All Quarters
Q2 2023 →